NCT06765265RecruitingPhase 4
Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
Source: ClinicalTrials.gov · Last updated 11 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 152 (estimated)
- First submitted
- 3 Jan 2025
- Start date
- 5 Jan 2025
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- King Edward Medical University
- Diseases
- Coronary artery disease
- NCT number
- NCT06765265
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 152
- From 5 Jan 2025 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)
Other illness
- hypersensitivity to statins
Other
- Hypercalcemia
- hypocalcemia
- pregnancy
- lactation
- hypothyroidism
- Deranged LFTs \& RFTs
Who the study is looking for
- Acute Coronary Syndrome
- 25 OH-Vitamin D levels between 30-70ng/ml
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| King Edward Medical University Coordinator of this site? Confirm its status | Lahore | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.